Exercise Training in Heart Failure: Current Evidence and Future Directions. [Review]

Eleyan, L.; Gonnah, AR.; Farhad, I.; Labib, A.; Varia, A.; Eleyan, A.; Almehandi, A.; Al-Naseem, AO.; Roberts, DH.

Exercise Training in Heart Failure: Current Evidence and Future Directions. [Review]

All Authors

Eleyan, L.

Gonnah, AR.

Farhad, I.

Labib, A.

Varia, A.

Eleyan, A.

Almehandi, A.

Al-Naseem, AO.

Roberts, DH.

LTHT Author

Eleyan, Loay

LTHT Department

Doctors' Rotation

Publication Date

2025

Item Type

Journal Article
Review

Abstract

Heart Failure (HF) is a prevalent condition which places a substantial burden on healthcare systems worldwide. Medical management implemented with exercise training (ET) plays a role in prognostic and functional capacity improvement. The aim of this review is to determine the effect of exercise training (ET) on HFpEF and HFrEF patients as well as exercise modality recommendations in frail and sarcopenic subpopulations. Pharmacological therapy structures the cornerstone of management in HF reduced ejection fraction (HFrEF) and aids improved survival rates. Mortality reduction with pharmacological treatments in HF preserved ejection fraction (HFpEF) are yet to be established. Cardiac rehabilitation (CR) and ET can play an important role in both HFrEF and HFpEF. Preliminary findings suggest that CR significantly improves functional capacity, exercise duration, and quality of life. ET has shown beneficial effects on peak oxygen consumption (pVO2) and 6 min walk test distance in HFrEF and HFpEF patients, as well as a reduction in hospitalisation and mortality rates; however, the limited scope of larger trials reporting on this underscores the need for further research. ET also has been shown to have beneficial effects on depression and anxiety levels. High-intensity training (HIT) and moderate continuous training (MCT) have both shown benefits, while resistance exercise training and ventilatory assistance may also be beneficial. ET adherence rates are higher when enrolled to a supervised programme, but prescription rates remain low worldwide. Larger robust trials are required to determine ET's effects on HF, as well as the most efficacious and personalised exercise prescriptions in HF subtypes.